Electronic Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Implantable Drug Delivery Devices, Smart Metered Dose Inhalers), By Application (Diabetes, Oncology), By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global electronic drug delivery devices market size was estimated at USD 62.21 billion in 2024 and is projected to grow at a CAGR of 8.14% from 2025 to 2030. The increasing prevalence of chronic diseases and growing geriatric population, rising preference for home healthcare, increasing awareness of personalized medicine, and the integration of digital technologies are the factors affecting the market's growth. For instance, in September 2024, SHL Medical launched Elexy, a reusable electromechanical drug delivery device designed to support digital therapeutics and a wide array of specialty formulations. This device offers cellular and Bluetooth connectivity options, which facilitate the collection of comprehensive data related to the drug, its container, and the device itself use.

The growing prevalence of chronic diseases is significantly contributing to the growth of the drug delivery devices market. Chronic diseases such as diabetes, cancer, cardiovascular diseases, and respiratory disorders require long-term management, frequently involving daily or regular drug administration to manage symptoms, prevent complications, and improve quality of life. Some of the devices that can be used for this include insulin pumps, inhalers, patches, implantable devices, and continuous glucose monitors.

As per a report by the World Health Organization (WHO), cardiovascular diseases (CVD) are the leading cause of death globally and take an estimated 17.9 million lives each year. Some of the cardiovascular diseases include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. Furthermore, according to the WHO, by 2050, the number of new cancer cases is projected to rise by over 35 million.

Estimated Number of New Cancer Cases for all Cancer Types from 2022 to 2030, Incidence, Both Sexes, Age [0-85+]

Source: International Agency for Research on Cancer (IARC), GVR Analysis

The rising preference for home healthcare is a significant driver of growth in the electronic drug delivery devices market, as more patients and healthcare systems seek to shift care from hospitals and clinics to home settings. Home healthcare offers patients comfort, privacy, and the convenience of receiving treatment in a familiar environment while reducing the strain on healthcare facilities. This shift is driven by several factors, such as lowering healthcare costs, improving patient outcomes, and increasing access to care.

As patients increasingly prefer to manage their health conditions at home, there is a growing demand for electronic drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering convenience and autonomy. For instance, in October 2023, Victrex plc, known for its innovative PEEK biomaterial solutions, introduced an advanced product, the VICTREX PC101 grade, specifically designed for drug delivery and pharmaceutical contact applications. This launch aligns with the growing trend of utilizing drug delivery devices in homecare environments, enhancing accessibility for patients seeking innovative solutions.

Furthermore, integrating digital technologies has played a crucial role in transforming drug delivery and improving its precision and safety. Incorporating digital health technologies (DHTs) offers several advantages in developing drug delivery devices. These advancements include electronic sensors, computing platforms, and information technology, all providing new opportunities for collecting clinical trial data directly from patients.

These technologies also include smart drug delivery devices connected to mobile apps, cloud platforms, and digital monitoring systems, enabling real-time tracking and management of medical administration. This digital integration enhances treatment efficiency, improves patient adherence, and allows healthcare providers to monitor patients remotely, reducing the need for in-person visits. For instance, in October 2022, the NEMERA Group, a design, development, and manufacturing company for drug delivery device solutions, partnered with Zollner Elektronik AG, an electronic manufacturing service provider. With this partnership, Zollner will support the design, development, and manufacturing of electronic drug delivery devices for Nemera’s proprietary and customer-owned products, beginning with Nemera’s Symbioze wearable injection device.

Market Concentration & Characteristics

The electronic drug delivery devices market exhibits moderate industry concentration, with several key players dominating the market. Initiatives to raise awareness and knowledge about advanced drug delivery and personalized medicine further stimulate market growth.

The electronic drug delivery devices industry is characterized by high innovation. Advances in microelectronics, biotechnology, and materials science have driven the development of sophisticated devices such as smart inhalers, patch pumps, and implantable drug delivery systems. These innovations are focused on improving patient compliance, enhanced drug efficacy, and precise dosage control. Additionally, personalized medicine trends push for customized devices tailored to individual patient needs, fostering continuous innovation in the sector.

Regulatory frameworks significantly influence the electronic drug delivery device industry, as these products are classified under medical devices and pharmaceutical regulations in many regions. Compliance with regulatory requirements, such as US FDA guidelines or EU CE marking, is imperative for market entry and consumer trust. These regulations govern various aspects, including product design, manufacturing processes, and post-market surveillance, influencing product development timelines and market access. Evolving regulatory landscapes necessitate continuous monitoring and adaptation by industry players to ensure compliance and navigate market dynamics effectively.

Mergers and acquisitions in the drug delivery devices industry are rising due to the need for research and development, reflecting the industry's dynamic nature. Companies engage in mergers and acquisitions to expand their product portfolio, enter new markets, acquire cutting-edge technologies, and achieve economies of scale. For instance, in September 2023, Abbott Laboratories acquired Bigfoot Biomedical, Inc., a smart insulin management company, and the company’s smart insulin management system, which simplifies continuous glucose monitors (CGMs) and the produced data. This system also works exclusively with Abbott Laboratories’ FreeStyle Libre CGM technology.

The electronic drug delivery device industry faces competition from traditional and emerging drug delivery methods. Conventional drug delivery devices and systems like oral tablets, injections, and transdermal patches remain prevalent due to their cost-effectiveness and simplicity. However, electronic devices offer advantages such as improved precision, controlled release, and reduced side effects, which are driving their adoption. However, the high cost of electronic devices and the need for specialized training can limit their acceptance in certain markets. Alternative drug delivery technologies, like biodegradable implants and nanotechnology-based systems, also add to the competitive landscape.

The electronic drug delivery devices industry is expanding globally, driven by rising healthcare spending, technological innovation, and demand for diagnostics. Regional expansion helps companies enter new markets, address local needs through research, and boost market share. For example, Stevanato Group partnered with Recipharm to develop pre-fillable syringes for a soft mist inhaler targeting sensitive biologics in 2023.

Product Insights

The implantable drug delivery devices segment accounted for the largest revenue share of 33% in 2024. Implantable drug delivery devices are advanced medical devices designed to deliver therapeutic agents directly to specific body areas over an extended period. Unlike traditional drug delivery devices and methods, like oral medications or injections, implantable devices are surgically placed inside or on the body, which provide controlled, sustained, sustained release of drugs. These devices can be used to treat various medical conditions, including chronic pain, cancer, hormonal imbalances, and neurological disorders. Some of the major advantages of these devices include their ability to provide localized treatment, ensure direct delivery of drugs to target tissue, reduce the risk of side effects, and improve therapeutic outcomes. Some implantable devices include pumps, microchips, biodegradable devices, and implantable reservoir systems.

The smart metered dose inhalers (MDIs) segment is expected to grow at the fastest CAGR of 11.69% over the forecast period. Smart MDIs are advanced respiratory drug delivery devices that combine traditional metered dose inhalers with smart technology, which enhances the accuracy, convenience, and effectiveness of drug administration for individuals with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Smart MDIs address these limitations by incorporating sensors, Bluetooth functionality, and data-monitoring capabilities. These features enable real-time usage tracking, patient feedback, and remote monitoring. For example, in February 2022, AptarGroup, Inc. introduced HeroTracker Sense-a digital solution designed to convert conventional pressurized metered dose inhalers (pMDIs) into smart, connected health devices.

Application Insights

The diabetes segment accounted for the largest revenue share of the electronic drug delivery devices market in 2024. The factors affecting the market growth include high prevalence and growing patient population, technological advancements in diabetes care, and growing market demand, along with reimbursement support. According to the International Diabetes Federation (IDF), by 2050, 1 in 8 adults, or approximately 853 million, will be living with diabetes. The key contributors to the rise in this disease are urbanization, the growing aging population, decreasing levels of physical activity, and the increasing prevalence of obesity among people. In February 2024, Tandem Diabetes Care, Inc. announced the U.S. launch of the Tandem Mobi, which is an automated insulin delivery system for people living with diabetes.

The oncology segment is expected to grow at the fastest CAGR during the forecast period due to the increasing advancements in cancer therapies, growing incidence of cancer burden, enhanced patient convenience and compliance, such as outpatient treatment, and reduced hospital stays. Companies are increasing their manufacturing and research for increasing the use of electronic drug delivery devices for oncology. As an example, in February 2023, PharmaDrug Inc. partnered with PharmaTher Holdings Ltd. to explore the use of PharmaTher’s innovative microneedle patch (MN-Patch) technology for delivering N, N-Dimethyltryptamine (DMT)..

Regional Insights

North America Electronic Drug Delivery Devices Market Trends

The North American electronic drug delivery devices market dominated the global market and accounted for the 43.36% revenue share in 2024. Some key factors contributing to the growth include technological advancements, an increasing prevalence of chronic diseases, and rising demand for patient-centric drug delivery solutions. The U.S. and Canada are at the forefront of this growth, with the healthcare systems shifting towards personalized medicine and smart drug delivery solutions. Furthermore, the presence of key industry players and startups focusing on next-generation drug delivery solutions has intensified competition and accelerated product innovation.

U.S. Electronic Drug Delivery Devices Market Trends

The electronic drug delivery devices market in the U.S. held a significant revenue share of North America's electronic drug delivery devices market in 2024, driven by factors such as the increasing prevalence of chronic diseases, rising demand for at-home healthcare solutions, and continuous technological advancements in drug administration. Furthermore, the growing incidence of diabetes, respiratory disorders, and cardiovascular diseases has led to an increased reliance on innovative drug-delivery devices that enhance treatment efficacy and patient compliance. For instance, according to the Centers for Disease Control and Prevention’s (CDC) National Diabetes Statistics Report, over 130 million adults in the U.S. are affected by diabetes or prediabetes.

The below chart indicates the estimated prevalence of diabetes across U.S. states in 2025:

Europe Electronic Drug Delivery Devices Market Trends

The European electronic drug delivery devices market is witnessing growth fueled by the increasing prevalence of chronic diseases, technological advancements, and regulatory support for innovative drug delivery devices. For instance, around 35% of the European Union’s (EU) population reported having a long-standing chronic health condition in 2023. Additionally, the shift towards home-based care further pushes the demand for user-friendly and automated drug delivery devices, reducing the dependency on healthcare facilities.

The electronic drug delivery devices market in the UK is one of the key markets in the region. The rising burden of diabetes, respiratory conditions, and cardiovascular diseases has fueled the demand for advanced drug delivery systems that enhance patient compliance and therapeutic outcomes. According to Diabetes UK, one in five adults living in the UK are diabetic or prediabetic. Additionally, the government of the UK also has the NHS Diabetes Prevention Programme, which is a collaboration between NHS England, Public Health England, and Diabetes UK to help individuals reduce their risk of developing Type 2 diabetes.

France electronic drug delivery devices market is expected to grow over the forecast period. Regulatory support and favorable reimbursement policies have been critical in shaping the landscape of drug delivery devices in France. The French National Authority for Health (HAS) and the National Health Insurance (Assurance Maladie) have established reimbursement frameworks for various digital health and smart drug delivery devices, encouraging healthcare providers to integrate them into patient care. For instance, in May 2024, the Omnipod 5 insulin patch pump was included in France’s reimbursable products list, as the Fédération Française des Diabetiques announced.

The electronic drug delivery devices industry in Germany is projected to expand in the forecast period. Germany’s drug delivery devices market is witnessing significant growth due to increasing chronic disease prevalence, advancements in smart medical technology, and a strong regulatory framework that supports innovation. Also, Germany's position as a leader in pharmaceutical and biotechnology R&D is a key driver for the adoption of innovative drug delivery devices.

Italy electronic drug delivery devices market is projected to expand in the forecast period due to the increasing demand for advanced therapeutic solutions, particularly for chronic disease management. According to the Eurostat data in January 2024, Italy has the oldest population in Europe, with an average median age of more than 48, driving the need for efficient and patient-friendly drug administration technologies.

Asia Pacific Electronic Drug Delivery Devices Market Trends

The electronic drug delivery devices market in the Asia Pacific region is projected to experience the fastest growth during the forecast period. China and Japan are expected to dominate this market. Additionally, the availability of trained professionals and the development of healthcare facilities are anticipated to contribute significantly to market growth.

Japan electronic drug delivery devices market is expected to grow the fastest. Japan’s regulatory framework is evolving to accommodate innovative digital health technologies, allowing speedier market entry for drug delivery devices that integrate with the country’s well-developed telehealth infrastructure. For instance, in July 2024, Koru Medical Systems received regulatory clearance in Japan for its FreedomEdge Infusion System, enabling the delivery of multiple drugs. This portable system enhances patient care by allowing convenient administration of large-volume therapies at home and in clinics.

Furthermore, the country’s aging population, increasing prevalence of chronic diseases, and strong government initiatives support digital healthcare. For instance, in September 2024, according to the Ministry of Internal Affairs and Communications, Japan’s elderly population reached a record 36.25 million, with those aged 65 or older comprising nearly one-third (29.3%) of the total population. This high proportion of the elderly population increases the demand for advanced and electronic drug delivery systems to ensure precise and controlled medication administration.

The electronic drug delivery devices market in China is expected to grow over the forecast period. The market in China is driven by the aging population, increasing chronic disease prevalence, technological advancements, and expanding government initiatives in digital healthcare. According to a report published by the Ministry of Civil Affairs and China National Committee, China's population aged 60+ reached 297 million, 21.1% of the total, with those aged 65+ at 216.76 million (15.4%). The rising incidence of diabetes, respiratory disorders, and cardiovascular diseases is driving demand for advanced drug delivery solutions.

India electronic drug delivery devices market is expected to grow over the forecast period.India’s drug delivery devices market is experiencing significant expansion, driven by rising chronic disease prevalence, technological advancements, the development of the healthcare sector, and the increasing prevalence of conditions such as diabetes and asthma. For instance, according to a report published by the WHO on disease prevalence in India in March 2023, around 75 million people in India are estimated to be on treatment for hypertension and diabetes by 2025, with around one in every four adults being hypertensive and one in every ten adults being diabetic. Moreover, according to the same report, NCDs are responsible for around 63% of mortalities in the country. Similarly, according to the Global Asthma Report, around 35 million people in India have asthma. Such a high prevalence of various diseases significantly increases the demand for a wide range of advanced drug-delivery devices in the country.

Latin America Electronic Drug Delivery Devices Trends

The rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular disorders in the region drives the electronic drug delivery devices market in Latin America. Countries such as Brazil and Argentina are witnessing increased adoption of innovative drug delivery technologies due to their large patient populations and improved healthcare infrastructure.

Middle East & Africa Electronic Drug Delivery Devices Trends

The Middle East & Africa electronic drug delivery device market region is witnessing rising adoption of these devices, driven by the growing prevalence of chronic diseases, expanding healthcare infrastructure, and increasing patient preference for connected user-friendly solutions. Innovation in wearable injectors and smart inhalers is also accelerating, supported by government digital health initiatives and private investment.

The electronic drug delivery devices industry in Saudi Arabia is anticipated to expand in the forecast period. The factors affecting market growth include regulatory developments, advancing healthcare infrastructure and technological developments, and the growing demand for personalized medicine solutions.

Kuwait electronic drug delivery devices market is expected to witness moderate growth, driven by higher healthcare spending, growing awareness of health, and investments in healthcare infrastructure. Additionally, there is an increasing number of healthcare professionals. For instance, according to a report by the Ministry of Health of Kuwait, as of 2023, the workforce included 66,202 people, which included administrators, doctors, technicians, pharmacists, nursing staff, and others.

Key Electronic Drug Delivery Devices Company Insights

The electronic drug delivery devices market is highly competitive, with key players such as Medtronic, Becton, Dickinson and Company, Eli, Lilly and Company, AstraZeneca, and Insulet Corporation holding significant positions.

The major companies are undertaking various organic and inorganic strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion for serving the unmet needs of their customers.

Recent Developments

• In January 2025, West Pharmaceutical Services introduced the Daikyo PLASCAP Ready-to-Use Validated (RUV) closures. These closures, crafted from metal-free polypropylene and featuring built-in stoppers, deliver a simplified, single-step solution for sealing vials. Their design is particularly suited to support the handling and storage needs of advanced therapies such as gene and cell-based treatments.

• In October 2024, Qnovia, Inc., a pharmaceutical firm, secured FDA clearance for its inhaled drug delivery system, RespiRx (QN-1), a nicotine inhaler. This inhalable nicotine replacement therapy (NRT) is intended to support individuals trying to quit smoking.

• In August 2024, Insulet's Omnipod 5 Automated Insulin Delivery System received FDA clearance for individuals aged 18 and older with type 2 diabetes. This expansion makes Omnipod 5 the first and only automated insulin delivery system approved for both type 1 and type 2 diabetes management.

Electronic Drug Delivery Devices Market Report Scope

Global Electronic Drug Delivery Devices Market Report Segmentation

This report forecasts global, regional, and country level revenue growth and analyzes the latest industry trends and opportunities in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global electronic drug delivery devices market report based on the  product, application, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Smart Infusion Pumps (Infusion Systems)

    • Non-biologic Smart Infusion Systems

    • Biologic Smart Infusion Systems

      • Smart Infusion Insulin Pumps

      • Others

  • Smart Metered Dose Inhalers (Inhalation Devices)

  • Implantable Drug Delivery Devices

    • Biologic Implantable Drug Delivery Devices

    • Non-biologic Implantable Drug Delivery Devices

  • Smart Transdermal Patches (Transdermal Delivery Systems)

  • Others

• Application Outlook (Revenue, USD Million 2018 - 2030)

  • Diabetes

  • Respiratory Diseases

  • Oncology

  • Cardiology

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait